Results 121 to 130 of about 25,910 (264)

Advances in Neoantigen-Based Cancer Vaccines

Neoantigen-based immunotherapies harness somatic mutations as tumor-specific targets and represent a major advance in personalized cancer treatment.
Yusuke Nakamura, An-Chih Wu, Kazuma Kiyotani   +2 more
core   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

Cancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang, Chenfei Zhao, Jingru Shi, Shiwei Liu, Yi Chen, Jujuan Wang, Zhengxu Sun, Sanmei Wang, Lei Fan, Jin Fan, Xiaoyan Qu   +10 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Type 1 diabetes (T1D) is a self‐driving autoimmune condition leading to the death of insulin‐producing β‐cells of the pancreas. β‐cell‐reactive immune cell extravasation into the intra‐islet space is fuelled by a cycle of inflammation including immune, vascular and endocrine dysfunction. Since clinical pancreatic biopsy is contraindicated,
Maja Witowska, Luigi Margiotta‐Casaluci, Periklis Pantazis, Margarita Dominguez‐Villar, Victoria Salem   +4 more
wiley   +1 more source

New insights into β‐cell vulnerability in type 1 diabetes—Lessons from nature

Diabetic Medicine, EarlyView.
Abstract Type 1 diabetes results from an autoimmune‐mediated destruction of pancreatic β‐cells, yet considerable heterogeneity exists regarding disease onset, progression and severity. Emerging evidence suggests that this variability reflects not only differences in immune responses, but also differences in the architecture and immune landscape of the ...
Kathryn Murrall, Teifion Luckett, Christiana Lekka, Stephanie L. Hunter, Sylvie Agnello, Peter Ferris, Emma Haxton, Christine S. Flaxman, Abirami Kannan, Xinpeng Dun, Sarah J. Richardson   +10 more
wiley   +1 more source

Dendritic cell-derived exosomes induce monocyte antigen-presentation and immune amplification in neoantigen vaccine therapy [PDF]

Mature dendritic cells release exosomes; however, the immunological role of exosomes in dendritic cell vaccine therapy remains unclear. We examined the immunogenicity of neoantigen peptide-pulsed dendritic cell-derived exosomes (Neo-P DEX) and ...
Yusuke Nakamura, Sachiko Yoshimura, Takashi Morisaki, Hideya Onishi, Poh Yin Yew, Hiroto Tanaka, Shinji Morisaki, Takafumi Morisaki, Masafumi Nakamura, Shinichiro Nakagawa, Masayo Umebayashi, Kenta Tsujimura, Takehiro Torisu, Makoto Kubo, Takanari Kitazono, Norihiro Koya, Kazuma Kiyotani   +16 more
core   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Tumor neoantigens and tumor immunotherapies

AGING MEDICINE
AbstractAs a high‐risk group of patients with cancer, the elderly exhibit limited efficacy with traditional treatments. Immunotherapy emerges as a promising adjunctive therapeutic approach that holds potential in addressing the needs of geriatric patients with cancer.
Wang Jiani, Tan Qin, Ma Jie
openaire   +3 more sources

A guide to studying tumour‐T‐cell interactions using in vitro coculture assays

The FEBS Journal, EarlyView.
In vitro tumour‐T‐cell coculture systems provide a controlled way to study how T cells recognise and kill tumour cells. Different tumour models can be combined with antigen‐specific TCR or CAR T cells, while antigen presentation, cytokines, drugs and tumour genetics can be manipulated.
Nooshin Khoshdoozmasouleh, Conor J. Kearney   +1 more
wiley   +1 more source